Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $3.6 million.

  • Catalyst Pharmaceuticals' Change in Account Payables fell 1976.61% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 million, marking a year-over-year decrease of 13542.0%. This contributed to the annual value of $1.8 million for FY2024, which is 8338.26% down from last year.
  • Catalyst Pharmaceuticals' Change in Account Payables amounted to $3.6 million in Q3 2025, which was down 1976.61% from -$5.7 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Change in Account Payables peaked at $10.2 million during Q4 2023, and registered a low of -$5.7 million during Q2 2025.
  • For the 5-year period, Catalyst Pharmaceuticals' Change in Account Payables averaged around $254736.8, with its median value being $177000.0 (2023).
  • Examining YoY changes over the last 5 years, Catalyst Pharmaceuticals' Change in Account Payables showed a top increase of 893750.0% in 2022 and a maximum decrease of 87369.86% in 2022.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Change in Account Payables stood at $16000.0 in 2021, then surged by 8937.5% to $1.4 million in 2022, then soared by 605.19% to $10.2 million in 2023, then tumbled by 50.67% to $5.0 million in 2024, then decreased by 29.07% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, -$5.7 million for Q2 2025, and -$5.4 million during Q1 2025.